GW Pharmaceuticals PLC- (NASDAQ:GWPH)’s share price traded down 3.6% on Tuesday . The stock traded as low as $81.72 and last traded at $82.05, with a volume of 271,153 shares trading hands. The stock had previously closed at $85.07.

Several equities analysts recently weighed in on the company. Vetr lowered GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating and set a $91.16 price target for the company. in a research note on Monday, July 25th. Zacks Investment Research lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Cantor Fitzgerald lowered their price objective on GW Pharmaceuticals PLC- from $181.00 to $165.00 and set a “buy” rating on the stock in a report on Tuesday, August 9th. Cowen and Company reiterated a “buy” rating and issued a $135.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Tuesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $130.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Wednesday, June 29th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $126.01.

The company’s market cap is $1.78 billion. The firm has a 50-day moving average of $92.38 and a 200 day moving average of $76.75.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $1.15. The business had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.63 million. GW Pharmaceuticals PLC-‘s quarterly revenue was down 73.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.09) EPS. On average, equities analysts predict that GW Pharmaceuticals PLC- will post ($3.61) earnings per share for the current year.

A hedge fund recently raised its stake in GW Pharmaceuticals PLC- stock. Trexquant Investment LP boosted its stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 188.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,719 shares of the biopharmaceutical company’s stock after buying an additional 15,509 shares during the period. Trexquant Investment LP owned approximately 0.11% of GW Pharmaceuticals PLC- worth $1,647,000 as of its most recent SEC filing.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.